Trump Sets Pharma Tariffs Deadline. The Fallout for Lilly, Pfizer, Other Drugmakers
AstraZeneca And Daiichi Sankyo's ENHERTU Followed By THP Shows Improved Safety Profile Vs. Standard Of Care
AstraZeneca Reports Results From DESTINY-Breast11 Trial
AstraZeneca And Daiichi Sankyo's ENHERTU Achieves Significant PCR Gains With Improved Safety Profile In Early HER2 Positive Breast Cancer Patients
Trump wants to impose tariffs on Pharmaceuticals: Pharmaceutical companies are busy stockpiling, and the import volume in the USA surged in March.
① The volume of Pharmaceutical imports in the USA surged in March, as pharmaceutical companies stockpiled products in anticipation of potential tariffs; ② A report released by the US Department of Commerce on Tuesday showed that the total value of Pharmaceutical imports in March exceeded 50 billion USD, equivalent to 20% of the total Pharmaceutical imports for the entire year of 2024.
Tempus AI Raises Revenue Guidance to $1.25B for 2025, Supported by New $200M AstraZeneca Deal
AstraZeneca Hits 4-week High
AstraZeneca (AZN.US) BTK inhibitor new indication approved by the EU for the treatment of mantle cell lymphoma.
AstraZeneca (AZN.US) announced that acalabrutinib in combination with bendamustine and rituximab has been approved in the European Union for the treatment of adult patients with mantle cell lymphoma (MCL) who have not received prior treatment and are not suitable for autologous stem cell transplantation.
AstraZeneca's Calquence Regimen Wins EU Approval for Mantle Cell Lymphoma
AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye
Calquence Plus Chemoimmunotherapy Approved in the EU as First and Only BTK Inhibitor for 1st-line Mantle Cell Lymphoma
India Offers US Reciprocal Zero Tariffs on Steel, Auto Parts, Pharmaceutical Drugs, Bloomberg Reports
AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
AstraZeneca Announces KALOS, LOGOS Trials Met All Primary Endpoints
AstraZeneca's Fixed-Dose Triple-Combination Therapy BREZTRI AEROSPHERE Meets Primary Endpoints In KALOS And LOGOS Phase III Trials In Asthma
AstraZeneca Reported High-level Results From The Phase 3 KALOS and LOGOS Trials, Showing Fixed-dose Triple-combination Therapy Breztri Aerosphere Met All Primary Endpoints In Patients With Uncontrolled Asthma
AstraZeneca's Asthma Drug Improves Lung Function in Late-stage Studies
AstraZeneca Director Invests in Company Shares
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty